empagliflozin 10mg

DRUG3 trials

Sponsors

Boehringer Ingelheim, University of Erlangen-Nürnberg Medical School, Chong Kun Dang Pharmaceutical

Conditions

Chronic Heart FailureDiabete Type 2Diabetes Mellitus, Type 2

Phase 2

Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

CompletedNCT03128528

University of Erlangen-Nürnberg Medical SchoolChronic Heart Failure

Start: 2017-07-01End: 2020-04-30Updated: 2020-09-28

Phase 4

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

CompletedNCT02589626

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2015-10-29End: 2017-06-02Updated: 2019-01-07

Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Not yet recruitingNCT07365358

Chong Kun Dang PharmaceuticalDiabete Type 2

Start: 2026-03-01End: 2027-08-01Target: 200Updated: 2026-01-26

Related Papers

Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.

2025-11-04

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

Clinical Research in Cardiology2022-10-2656 citations

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.

2021-11-0937 citations

VASCULAR REMODELING OF RETINAL VESSELS IN PATIENTS WITH CONGESTIVE HEART FAILURE

Journal of Hypertension2019-06-22

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.

2019-03-2519 citations

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

2018-01-04127 citations